期刊文献+

TLR7/8配体(R848)对人NK细胞杀伤功能的作用及其机制的探讨 被引量:4

The effects of R848 on the cytotoxicity of human natural killer cells and its mechanism
原文传递
导出
摘要 目的研究R848对人自然杀伤细胞(NK)杀伤功能的作用及其机制。方法分离健康志愿者外周血单个核细胞(PBMC)、纯化NK细胞,加或不加R848进行培养。分别在0、2、6、24、48h收集培养细胞,流式细胞术检测R848对NK细胞表面活化分子CD25和CD69表达的影响;检测R848活化的NK细胞杀伤靶细胞K562的作用、通过检测颗粒酶A、B、穿孔素、TRAIL和NK细胞与靶细胞共孵育后CD107a/b的表达,探讨R848促进NK细胞的杀伤功能机制。结果 R848活化的NK细胞在培养24h时CD69和CD25分子的表达百分率和平均荧光密度达到峰值,随后活化分子的表达有所下降;R848活化的NK细胞对靶细胞的杀伤功能明显增强,TRAIL在不同NK细胞亚群的表达显著增加(P<0.05)。当NK细胞与K562共孵育后,R848活化的NK细胞表面CD107a/b的表达较未刺激条件明显增加。结论 R848可直接作用于NK细胞促进其杀伤功能,其作用机制与NK细胞活化后释放颗粒酶和穿孔素增加,并且TRAIL的表达增加有关。 This paper is aimed to study the effects of R848 on the cytotoxicity of human natural killer cells and its mechanism.We isolated peripheral blood mononuclear cell(PBMC) and purified NK cells from normal human peripheral blood,and then cultured them with R848.The cultured cells were harvested at different time points (0,2,6,24 and 48 hours) for follow tests.The expression of activating molecules such as CD69 and CD25 were detected by flow cytometry;the cytolytic activity and mechanism of R848-activated NK cells were evaluated by detecting the expression of granzymes,perforin,TRAIL,and CD107a/b.The results indicated that the percentage and MFI of the expression of CD69 and CD25 molecules on R848-activated human NK cells reached to peak levels after culturing for 24 hours and then decreased slightly;the cytotoxicity of R848 activated NK cells were enhanced significantly.After coincubation with the K562 target cells the degranulation of granzymes and perforin of R848 activated NK cells were more significant than those of the unstimulated cells.Therefore,the expression of CD107a/b and TRAIL was increased (P〈0.05).This study provides valuable information that R848 can directly promote the cytotoxic activity of human NK cells by enhancing the degranulation of granzymes and perforin,and by up-regulating the expression of TRAIL.
出处 《免疫学杂志》 CAS CSCD 北大核心 2010年第8期657-660,共4页 Immunological Journal
基金 教育部博士学科点专项科研基金资助项目(20070558213 20090171120050新教师类) 广东省自然科学基金博士启动项目(8451008901000131) 广东省医学科研基金资助项目(A2009161)
关键词 NK细胞 TLR R848 杀伤功能 NK cell TLR R848 Cytotoxicity
  • 相关文献

参考文献8

  • 1Girart MV, Fuertes MB, Domaica CI, eta[. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12 [J]. J Immunol, 2007, 179(6):3472-3479.
  • 2尹凌凡,范艳莹,李丽,吴长有.Toll样配体(R-848)与IL-12对人NK细胞亚群IFN-γ产生的作用[J].细胞与分子免疫学杂志,2007,23(7):623-626. 被引量:9
  • 3范艳莹,吴长有.CFSE标记结合流式细胞术在研究NK细胞分裂与杀伤功能中的应用[J].免疫学杂志,2010,26(1):63-67. 被引量:7
  • 4Bourquin C, Schmidt L, Lanz AL, et al. Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7[J]. J Immunol, 2009, 183(10): 6078-6086.
  • 5Hart OM, Athie-Morales V, O'Connor GM, et al. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production [J]. J Immunol, 2005, 175(3):1636-1642.
  • 6Pries R, Wulff S, Kesselring R, et al. Up-regulation of NK cell function against head and neck cancer in response to ss-isRNA requires TLR7 [J]. Int J Oncol, 2008, 33 (5): 993-1000.
  • 7Toka FN, Nfon CK, Dawson H, et al. Accessory-cell-mediated activation of porcine NK ceils by toll-like receptor 7 (TLRT) and TLR8 agonists[J]. Clin Vaccine Immunol, 2009, 16(6):866-878.
  • 8闫小毅,曹雪涛(审校).TLR7介导抗病毒免疫应答研究进展[J].国外医学(免疫学分册),2005,28(5):292-295. 被引量:7

二级参考文献39

共引文献20

同被引文献35

  • 1李和军,张家永,李频,郑祥雄,周小玲.人CD40-IgG1Fc段融合蛋白对EBV转化的B细胞凋亡的影响[J].免疫学杂志,2009,25(3):279-282. 被引量:2
  • 2Cheung MC, Haynes AE, Meyer RM, et al. Rituximab in |ymphoma:a systematic review and consensus practiceguideline from cancer care ontario [J]. Cancer Treat Rev, 2007, 33(2): 161-176.
  • 3Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy[J]. J Immunol, 2005, 174(2): 817-826.
  • 4Shiokawa M, Takahashi T, Murakami A, et al. In vivo assay of human NK-dependent ADCC using nod/SClD/gammae (null) (NOG) miee[J]. Bioehem Biophys Res Commun, 2010, 399(4): 733-737.
  • 5Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximah in autoimmune disease--the immune complex decoy hypothesis [J]. Nat Clin Pract Rheumatol, 2007, 3(2): 86-95.
  • 6Fischer L, Penack O, Gentilini C, et al. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells[J]. Exp Hematol, 2006, 34(6): 753-759.
  • 7Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies [J]. PLoS One, 2007, 2(3): e326.
  • 8Di GN, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo [J]. J Immunol, 2003, 171(3): 1581-1587.
  • 9Klepfish A, Schattner A, Ghoti H, et al. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia [J]. Lancet Oncol, 2007, 8(4): 361-362.
  • 10Kumar V, All SR, Konrad S, et al. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice [J]. J Clin Invest, 2006, 116(2): 512-520.

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部